hrcak mascot   Srce   HID

Other

LIVER TRANSPLANTATION IN HEPATITIS B VIRAL INFECTION

TAJANA FILIPEC KANIŽAJ ; Merkur University Hospital, University of Zagreb, School of Medicine, Clinical Department of Internal Medicine, Zagreb, Croatia
VESNA ČOLIĆ-CVRLJE ; Merkur University Hospital, University of Zagreb, School of Medicine, Clinical Department of Internal Medicine, Zagreb, Croatia
ANNA MRZLJAK ; Merkur University Hospital, University of Zagreb, School of Medicine, Clinical Department of Internal Medicine, Zagreb, Croatia
RAJKO OSTOJIĆ ; Zagreb University Hospital Center, School of Medicine, University of Zagreb, Clinical Department of Internal Medicine, Department of Gastroenterology, Zagreb, Croatia

Fulltext: croatian, pdf (105 KB) pages 367-372 downloads: 555* cite
APA 6th Edition
FILIPEC KANIŽAJ, T., ČOLIĆ-CVRLJE, V., MRZLJAK, A. & OSTOJIĆ, R. (2013). TERAPIJA HEPATITISA B NAKON TRANSPLANTACIJE JETRE. Acta medica Croatica, 67 (4), 367-372. Retrieved from https://hrcak.srce.hr/113725
MLA 8th Edition
FILIPEC KANIŽAJ, TAJANA, et al. "TERAPIJA HEPATITISA B NAKON TRANSPLANTACIJE JETRE." Acta medica Croatica, vol. 67, no. 4, 2013, pp. 367-372. https://hrcak.srce.hr/113725. Accessed 26 Jul. 2021.
Chicago 17th Edition
FILIPEC KANIŽAJ, TAJANA, VESNA ČOLIĆ-CVRLJE, ANNA MRZLJAK and RAJKO OSTOJIĆ. "TERAPIJA HEPATITISA B NAKON TRANSPLANTACIJE JETRE." Acta medica Croatica 67, no. 4 (2013): 367-372. https://hrcak.srce.hr/113725
Harvard
FILIPEC KANIŽAJ, T., et al. (2013). 'TERAPIJA HEPATITISA B NAKON TRANSPLANTACIJE JETRE', Acta medica Croatica, 67(4), pp. 367-372. Available at: https://hrcak.srce.hr/113725 (Accessed 26 July 2021)
Vancouver
FILIPEC KANIŽAJ T, ČOLIĆ-CVRLJE V, MRZLJAK A, OSTOJIĆ R. TERAPIJA HEPATITISA B NAKON TRANSPLANTACIJE JETRE. Acta medica Croatica [Internet]. 2013 [cited 2021 July 26];67(4):367-372. Available from: https://hrcak.srce.hr/113725
IEEE
T. FILIPEC KANIŽAJ, V. ČOLIĆ-CVRLJE, A. MRZLJAK and R. OSTOJIĆ, "TERAPIJA HEPATITISA B NAKON TRANSPLANTACIJE JETRE", Acta medica Croatica, vol.67, no. 4, pp. 367-372, 2013. [Online]. Available: https://hrcak.srce.hr/113725. [Accessed: 26 July 2021]

Abstracts
Hepatitis B infection (HBV) causes liver cirrhosis and hepatocellular carcinoma that are indications for orthotopic liver transplantation (OLT). The outcome of OLT depends on the prevention of HBV reinfection and disease relapses. Out of 692 liver transplantations performed at Merkur University Hospital, 30 were done for HBV infection. These patients were treated with HBIG post OLT and lamivudine, entecavir, adefovir, tenofovir prior and post OLT. All patients became HBsAg and HBV DNA negative but four of them became HbsAg positive one year post OLT. The patients survived for 2 months to 7 years post OLT. With the introduction of HBIG immunoprophylaxis and new efficient antiviral treatment, the risk of relapse is only <10%, and survival is the same as in other indications for OLT. Because of the high cost and long-term treatment, efforts have been made to prevent recurrent HBV disease by using the schedules according to pre- and post-transplant HBV viremia and introducing the new potent antiviral analogue nucleos(t)ides.

Keywords
liver transplantation; HBV immunoprophylaxis; hepatitis B immunoglobulin; nucleos(t)ide analogues

Hrčak ID: 113725

URI
https://hrcak.srce.hr/113725

[croatian]

Visits: 1.015 *